Physician profile
Nicholas Telew
NPI 1144287723
$2,492.31
in general payments reported to CMS, 2019-2025
17 companies · $94.41 in 2025
The $94.41 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,127 · 2020: $459 · 2021: $46.71 · 2022: $224 · 2023: $311 · 2024: $230 · 2025: $94.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $608 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $608.41 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $864.13 | 2019-2024 | Austedo, Austedo Xr |
| Allergan, INC. | $347.56 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $205.48 | 2019-2025 | Ingrezza |
| Jazz Pharmaceuticals INC. | $155.53 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $126.47 | 2019-2025 | Rexulti |
| Alkermes, INC. | $121.33 | 2024 | Lybalvi |
| Lundbeck LLC | $114.09 | 2019-2020 | |
| Abbvie INC. | $90.42 | 2021-2023 | Vraylar |
| Vanda Pharmaceuticals INC. | $89.83 | 2019-2025 | Hetlioz, Fanapt |
| Janssen Scientific Affairs, LLC | $81.23 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $78.25 | 2019 | |
| Janssen Pharmaceuticals, INC | $58.63 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $47.27 | 2024 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $44.66 | 2019-2020 | |
| Tempus Ai, INC | $25.83 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.76 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Telew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.